Table 1.
Genotypic resistance mutations before switching to a double-boosted protease inhibitors regimen
| |
NNRTI |
PI |
Resistant Drugs |
||||
|---|---|---|---|---|---|---|---|
| Patient | 98 (G) | 103 (R/N) | 108 (I) | 135 (L/I/V) | 283 (I) | ||
| P1 |
G |
|
|
L |
|
63 P, 71 V, 77 wt/I, 93 L |
NVP L-lR |
| P2 |
|
N |
I |
N |
I |
10 V, 35 D |
EFV and NVP L-lR |
| P3 |
|
|
|
|
wt/I |
77I |
none |
| P4 |
63 P, 93 L |
none |
|||||
| P5 |
|
V |
|
V |
|
35 D, 60 E, 63 P |
none |
| P6 |
No mutations |
none |
|||||
| P7 | R | T | 10 V, 13 wt/V, 63 P, 77 I | none | |||